Malta - angličtina - Malta Medicines Authority

accord healthcare limited - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - antineoplastic agents

Malta - angličtina - Malta Medicines Authority

accord healthcare limited - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - antineoplastic agents

Malta - angličtina - Malta Medicines Authority

accord healthcare limited - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - antineoplastic agents

Malta - angličtina - Malta Medicines Authority

accord healthcare limited - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - antineoplastic agents

Malta - angličtina - Malta Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg - antineoplastic agents

Malta - angličtina - Malta Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg - antineoplastic agents

Izrael - angličtina - Ministry of Health

abic marketing ltd, israel - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan - * for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. * for the treatment of patients with small cell lung cancer.* for the treatment of patients with gastric cancer.* irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: lactic acid; sorbitol; water for injections; sodium hydroxide; hydrochloric acid - irinotecan indicated for the treatment of advanced colorectal cancer. -in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced cancer -as a single agent in patients who have failed 5-fluorouracil containing treatment regimen.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

pfizer limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - other antineoplastic agents

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 500 mg - injection, concentrated - excipient ingredients: sorbitol; lactic acid; sodium hydroxide; water for injections - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.